Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRCA wild-type
i
Other names:
BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset, BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
672
;
675
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
HRD + BRCA1 mutation (7)
HRD + BRCA2 mutation (7)
BRCA1 mutation + HR positive (3)
BRCA1 mutation + TMB-H (3)
BRCA2 mutation + HR positive (3)
HR positive + BRCA2 mutation (3)
BRCA1 2080delA + CCNE1 overexpression (2)
BRCA1 mutation + HER-2 negative (2)
HR negative + BRCA1 mutation (2)
HR positive + BRCA1 mutation (2)
BRCA2 mutation + HER-2 negative (2)
HR negative + BRCA2 mutation (2)
BAP1 negative + BRCA1 mutation (1)
BRCA1 hypermethylation (1)
BRCA1 mutation + AKR1C3 overexpression (1)
BRCA1 mutation + BRCA2 mutation + TMB-H (1)
BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)
BRCA1 mutation + PD-L1 expression (1)
BRCA1 mutation + RAD51B deletion (1)
BRCA1 mutation + RB1 deletion (1)
BRCA1 promoter methylation (1)
EGFR mutation + BRCA1 overexpression (1)
EGFR mutation + BRCA1 underexpression (1)
HR positive + BRCA1 mutation + PALB2 mutation (1)
PTEN deletion + BRCA1 mutation (1)
ALK rearrangement + BRCA2 F2801fs (1)
BRCA2 deletion + ATM mutation (1)
BRCA2 mutation + AKR1C3 overexpression (1)
BRCA2 mutation + ER positive (1)
BRCA2 mutation + ER positive + PGR positive (1)
BRCA2 mutation + RB1 deletion (1)
BRCA2 mutation + TMB-H (1)
BRCA2 mutation + TMB-L (1)
HR positive + BRCA2 mutation + PALB2 mutation (1)
ER positive + BRCA1 mutation (0)
ER positive + BRCA2 mutation (0)
HRD + BRCA1 mutation (7)
HRD + BRCA2 mutation (7)
BRCA1 mutation + HR positive (3)
BRCA1 mutation + TMB-H (3)
BRCA2 mutation + HR positive (3)
HR positive + BRCA2 mutation (3)
BRCA1 2080delA + CCNE1 overexpression (2)
BRCA1 mutation + HER-2 negative (2)
HR negative + BRCA1 mutation (2)
HR positive + BRCA1 mutation (2)
BRCA2 mutation + HER-2 negative (2)
HR negative + BRCA2 mutation (2)
BAP1 negative + BRCA1 mutation (1)
BRCA1 hypermethylation (1)
BRCA1 mutation + AKR1C3 overexpression (1)
BRCA1 mutation + BRCA2 mutation + TMB-H (1)
BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)
BRCA1 mutation + PD-L1 expression (1)
BRCA1 mutation + RAD51B deletion (1)
BRCA1 mutation + RB1 deletion (1)
BRCA1 promoter methylation (1)
EGFR mutation + BRCA1 overexpression (1)
EGFR mutation + BRCA1 underexpression (1)
HR positive + BRCA1 mutation + PALB2 mutation (1)
PTEN deletion + BRCA1 mutation (1)
ALK rearrangement + BRCA2 F2801fs (1)
BRCA2 deletion + ATM mutation (1)
BRCA2 mutation + AKR1C3 overexpression (1)
BRCA2 mutation + ER positive (1)
BRCA2 mutation + ER positive + PGR positive (1)
BRCA2 mutation + RB1 deletion (1)
BRCA2 mutation + TMB-H (1)
BRCA2 mutation + TMB-L (1)
HR positive + BRCA2 mutation + PALB2 mutation (1)
ER positive + BRCA1 mutation (0)
ER positive + BRCA2 mutation (0)
›
Associations
(19)
News
Trials
Search handles
@ErikaHamilton9
@RenoHemonc
@benjiwal
Search handles
@ErikaHamilton9
@RenoHemonc
@benjiwal
Filter by
Latest
10ms
Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer. @rcoledude #ovca #ASCO23 https://t.co/MNEYhPArVr (@OncLive)
10 months ago
Clinical
|
BRCA (Breast cancer early onset)
|
BRCA wild-type
|
Zejula (niraparib)
10ms
Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer. @rcoledude #ovca #ASCO23 https://t.co/Ggf2NEur0I (@OncLive)
10 months ago
Clinical
|
BRCA (Breast cancer early onset)
|
BRCA wild-type
|
Zejula (niraparib)
1year
True mCRPC pts are dwindling as most of them are started on ADT + NHT. For second line progression - BRCA/ CHEK2 m-> switch to single agent PARPi vs add it on top of NHT? For BRCA WT -Add PARPi and continue NHT? (@RenoHemonc)
1 year ago
Clinical
|
BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
|
BRCA wild-type
1year
Question for the experts: 54 yo woman with right TNBC pT2N1M0, BRCA wt. Met her after surgery 😒. @hoperugo @darioT_ @PTarantinoMD @Dr_RShatsky @fnacevedo @CesarGSanchezR @SuyogCancer (@benjiwal)
1 year ago
Surgery
|
BRCA (Breast cancer early onset)
|
BRCA wild-type
over1year
I do think in the TNBC, wild type BRCA space that have high TMB the use of immunotherapy has been disappointing. This is the space that clearly needs to most amount of work. (@DrARS77)
over 1 year ago
TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset)
|
TMB-H • BRCA wild-type
over1year
A phase II trial shows promising results with the PARP ihibitor talazoparib in patients with wild-type BRCA1/2 advanced #breastcancer https://t.co/J8nPPVWJ4b #fondazionebonadonna #oncology #cancerreseach @BianchiniGP @mauricallari @CarmenCriscit (@FondazioneBona1)
over 1 year ago
Clinical
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
BRCA wild-type
|
Talzenna (talazoparib)
over1year
12/18 #TumorBoardTuesday #BCSM 🌟We are now in the realm of ADCs! Because our 👩🏾 was: 🧬gBRCA wild type 🔬Her2 1+ 🔥#ProTip 👉🏽This is when I would send off genomic profiling if I hadn’t already. Then I have it. If I have a 🦄, I am ready to consider those agents in 3rd Line (@LauraSalamaMD)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
BRCA wild-type
over1year
@seemagulia1 @TataMemorial publish the only IPD metaanalysis PARP-inhibitors first-line ovarian cancer! Highly impactful results, clear benefit BRCA-mut or HRD-pos pts, but NOT in BRCA-wt/HRD-neg pts! @jamecancerdoc @AnaOaknin @myESMO @ASCOPost @sujithonco https://t.co/eXGgl26gAt (@ACTREC_TMC)
over 1 year ago
Retrospective data
|
BRCA (Breast cancer early onset)
|
BRCA wild-type
almost2years
Excited to see if BET + PARP can sensitize BRCA wt tumors to talazoparib. Looking at pts who have seen saci as well. #ASCO22 #bcsm (@ErikaHamilton9)
almost 2 years ago
Clinical
|
BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
BRCA wild-type
|
Talzenna (talazoparib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login